These findings suggest that signaling pathways modulated by the nSMase2/Smpd3 protein through lipid rafts might be novel therapeutic targets for DMD, via the stage-specific regulation of the expression levels of this protein and transcript, for example through exosomal transfer. Here, SMPD3 is linked to Duchenne muscular dystrophy.